Dine Brands Expands Global Footprint With New Deals and First Dual-Branded Applebee’s® and IHOP® Location in Honduras
Parent company of the world’s favorite restaurant brands extends dual-branded strategy to new international market.
Dine Brands International, an affiliate of Dine Brands Global, Inc., the parent company of Applebee’s®, IHOP®, and Fuzzy’sTaco Shop® restaurants, is further expanding its global footprint and unique dual-branded Applebee’s and IHOP concept to new international markets. Through a multi-unit development agreement with franchisee BLT Global Brands, the first dual-branded restaurant in San Pedro Sula, Honduras is planned to open on September 16, 2024.
Dine Brands' entry into Honduras marks a significant milestone in the company's international expansion strategy. This new location showcases the innovative dual-branded restaurant concept, which presents guests with two distinct IHOP and Applebee’s branded dining areas to choose from, while providing efficiencies in prototype design and operating model for franchisees. The unique dining experience allows guests to enjoy the best of both beloved brands, from IHOP's world-famous breakfast offerings to Applebee's diverse menu of casual dining favorites.
“We’re excited to bring IHOP and Applebee’s to Honduras. The country’s vibrant culture and growing economy make it an ideal location for this dual-branded concept, offering a unique blend of comfort and quality in a lively and inviting dining atmosphere,” said Thomas Christopher Talarico, CEO of BLT Global Brands.
“I am incredibly proud of the progress we are making to connect with and to expand to new guests around the world with the support of our franchisees,” added Scott Gladstone, Chief Development Officer, and President, International at Dine Brands Global. “By leveraging IHOP’s morning popularity and Applebee’s evening appeal, we can cover all day parts and bring delicious and memorable dining experiences with world-class service to guests every day. So far, we have been pleased with the improved overall performance and returns of our dual-branded restaurants.”
With this opening, the total number of international dual-branded restaurants will reach 13 locations across 7 markets: Mexico, Canada, UAE, Kuwait, Saudi Arabia, Peru and Honduras. Leveraging this innovative concept, Dine Brands International has recently secured agreements to develop at least 21 new locations, 13 of which will be dual-branded, in various international markets. These commitments represent both conversions of existing single-branded restaurants as well as new restaurants in both traditional and non-traditional channels, including airports and travel centers.
Dine Brands is seeking qualified Master Franchisees and Developers across select markets in Asia, including South Korea and Japan; select markets in Europe, including Spain; Brazil; and select territories in Mexico and Canada. For franchising opportunities, please visit https://franchise.ihop.com/en/applebees-co-branded-franchising.
About Dine Brands Global, Inc.
Based in Pasadena, California, Dine Brands Global, Inc. (NYSE: DIN), through its subsidiaries and franchisees, supports and operates restaurants under the Applebee’s Neighborhood Grill + Bar®, IHOP®, and Fuzzy’s Taco Shop® brands. As of June 30, 2024, these three brands consisted of close to 3,600 restaurants across 18 international markets. Dine Brands is one of the largest full-service restaurant companies in the world and in 2022 expanded into the Fast Casual segment. For more information on Dine Brands, visit the company’s website located at www.dinebrands.com.
BR-INTL
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909342681/en/
Contacts
Media Contact
Media Contact
Heather Mann
Director, Global Communications
Dine Brands Global, Inc.
Heather.mann@dinebrands.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom